FDA — authorised 18 September 1984
- Application: NDA018565
- Marketing authorisation holder: HIKMA
- Local brand name: INFUMORPH
- Indication: INJECTABLE — INJECTION
- Status: approved
🇺🇸 Intraosseous Morphine in United States
FDA authorised Intraosseous Morphine on 18 September 1984
Marketing authorisations
FDA — authorised 7 October 1986
- Application: ANDA071050
- Marketing authorisation holder: FRESENIUS KABI USA
- Local brand name: ASTRAMORPH PF
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 7 October 1986
- Application: ANDA071051
- Marketing authorisation holder: FRESENIUS KABI USA
- Local brand name: ASTRAMORPH PF
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 7 October 1986
- Application: ANDA071052
- Marketing authorisation holder: FRESENIUS KABI USA
- Local brand name: ASTRAMORPH PF
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 7 October 1986
- Application: ANDA071053
- Marketing authorisation holder: FRESENIUS KABI USA
- Local brand name: ASTRAMORPH PF
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Status: approved
Intraosseous Morphine in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Intraosseous Morphine approved in United States?
Yes. FDA authorised it on 18 September 1984; FDA authorised it on 7 October 1986; FDA authorised it on 7 October 1986.
Who is the marketing authorisation holder for Intraosseous Morphine in United States?
HIKMA holds the US marketing authorisation.